A highly potent non-nucleoside adenosine deaminase inhibitor: Efficient drug discovery by intentional lead hybridization

被引:53
作者
Terasaka, T
Kinoshita, T
Kuno, M
Nakanishi, I
机构
[1] Fujisawa Pharmaceut Co Ltd, Basic Res Labs, Yodogawa Ku, Osaka 5328514, Japan
[2] Fujisawa Pharmaceut Co Ltd, Med Chem Res Labs, Yodogawa Ku, Osaka 5328514, Japan
[3] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Yodogawa Ku, Osaka 5328514, Japan
关键词
D O I
10.1021/ja038606l
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We disclose herein the rapid discovery of the first highly potent (Ki = 7.7 nM) non-nucleoside adenosine deaminase (ADA) inhibitor based on the rational hybridization of two structurally distinct leads. Two micromolar inhibitors were discovered by a parallel rational design and random screening program, and individual crystal structures of bovine ADA in complexation with these inhibitors revealed several unknown binding sites and distinct binding modes. Using this information as the starting point, highly effective lead hybridization was achieved in only two structure-based drug design iterations. The conceptual approach illustrated by this example promises to be broadly useful in the search for new chemical entities and can contribute greatly to improve the overall efficiency and speed of drug discovery. Copyright © 2004 American Chemical Society.
引用
收藏
页码:34 / 35
页数:2
相关论文
共 19 条
[1]   TIGHT-BINDING INHIBITORS .4. INHIBITION OF ADENOSINE DEAMINASES BY VARIOUS INHIBITORS [J].
AGARWAL, RP ;
SPECTOR, T ;
PARKS, RE .
BIOCHEMICAL PHARMACOLOGY, 1977, 26 (05) :359-367
[2]  
AGARWAL RP, 1979, CANCER RES, V39, P1425
[3]   EFFECT OF CHIRALITY IN ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE (EHNA) ON ADENOSINE-DEAMINASE INHIBITION [J].
BESSODES, M ;
BASTIAN, G ;
ABUSHANAB, E ;
PANZICA, RP ;
BERMAN, SF ;
MARCACCIO, EJ ;
CHEN, SF ;
STOECKLER, JD ;
PARKS, RE .
BIOCHEMICAL PHARMACOLOGY, 1982, 31 (05) :879-882
[4]   PHASE-I STUDY OF 2'-3'-DIDEOXYINOSINE ADMINISTERED ORALLY TWICE DAILY TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX AND HEMATOLOGIC INTOLERANCE TO ZIDOVUDINE [J].
CONNOLLY, KJ ;
ALLAN, JD ;
FITCH, H ;
JACKSONPOPE, L ;
MCLAREN, C ;
CANETTA, R ;
GROOPMAN, JE .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (05) :471-478
[5]   ADENOSINE, AN ENDOGENOUS ANTIINFLAMMATORY AGENT [J].
CRONSTEIN, BN .
JOURNAL OF APPLIED PHYSIOLOGY, 1994, 76 (01) :5-13
[6]   Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes [J].
Franco, R ;
Valenzuela, A ;
Lluis, C ;
Blanco, J .
IMMUNOLOGICAL REVIEWS, 1998, 161 :27-42
[7]   PHARMACOKINETICS OF 2',3'-DIDEOXYINOSINE IN PATIENTS WITH SEVERE HUMAN IMMUNODEFICIENCY INFECTION .2. THE EFFECTS OF DIFFERENT ORAL FORMULATIONS AND THE PRESENCE OF OTHER MEDICATIONS [J].
HARTMAN, NR ;
YARCHOAN, R ;
PLUDA, JM ;
THOMAS, RV ;
WYVILL, KM ;
FLORA, KP ;
BRODER, S ;
JOHNS, DG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) :278-285
[8]   PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF 3'-AZIDO-3'-DEOXYTHYMIDINE - A NOVEL PYRIMIDINE ANALOG WITH POTENTIAL APPLICATION FOR THE TREATMENT OF PATIENTS WITH AIDS AND RELATED DISEASES [J].
KLECKER, RW ;
COLLINS, JM ;
YARCHOAN, R ;
THOMAS, R ;
JENKINS, JF ;
BRODER, S ;
MYERS, CE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (04) :407-412
[9]  
LAMBE CU, 1982, BIOCHEM PHARMACOL, V31, P535, DOI 10.1016/0006-2952(82)90156-3
[10]  
MCCONNELL WR, 1980, DRUG METAB DISPOS, V8, P5